SENVELGO® (velagliflozin oral solution) is a once-daily, liquid oral solution that can be administered directly into the cat’s mouth or applied onto a small amount of wet food.
Indications
Is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin
Supports
Reduces persistent hyperglycemia, leading to effective glycemic control in as soon as 1 week
Minimal risk of clinical hypoglycemic events
Precise dosing tailored to the cat’s weight
Significantly reduces the need for blood glucose monitoring
Well accepted by most cats
Easy storage—no refrigeration needed before or after opening
Dosage and Administration
Senvelgo should be administered using the dosing syringe provided in the package. The dosing syringe fits onto the bottle and as a body weight scale with increments per pound of body weight. The dose should be rounded down to the nearest pound. After administration, close the bottle tightly with the cap. If needed, the syringe can be cleaned with a clean, dry cloth Warnings Not for use in humans. Keep out of reach of children, wash hands after use. This product may cause mild eye irritation. Avoid contact with eyes. If the product accidentally gets into the eyes, rinse eyes immediately with plenty of water; if wearing contact lenses, rinse the eyes first then remove contact lens(es) and continue to rinse for 5-10 minutes. If eye irritation continues or accidental ingestion occurs, seek medical advice and provide this product information to the physician. Exposure to product may induce local or systemic allergic reaction in sensitized individuals. Oral exposure to velagliflozin may cause transient effects such as increased renal glucose excretion, increased urine volume, and hypoglycemia
Contraindications
Do not use Senvego in cats with diabetes mellitus who have been previously treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of Senvelgo in cats with insulin- dependent diabetes mellitus, or withdrawal of insulin and initiation of Senvelgo, is associate with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death